Twenty years of triptans in the United States Medicaid programs: Utilization and reimbursement trends from 1993 to 2013

Conclusions
The substantial increase in triptan prescriptions from 2009 to 2011, without being convincingly explained by either rising migraine prevalence or rising Medicaid enrollment, is suggestive of reduced access to these medications prior to 2009. Cost-containment policies may have inadvertently prevented Medicaid migraineurs from obtaining appropriate pharmacotherapy.

Prior presentations
An earlier version of this paper was presented as a poster at the Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, PA, May 2015, where it received a finalist award.

Source: Cephalalgia - December 1, 2016 Category: Neurology Authors: Xia, Y., Kelton, C. M., Wigle, P. R., Heaton, P. C., Guo, J. J. Tags: Original Articles Source Type: research